Rigor Reviewed

Rigor-Reviewed Manuscript

BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.

Name: Adcurare Rigor Record — BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.
Item: BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.
Rating: 96
Author: Adcurare

Schmidt AC, Fairlie L, Hellström E, Luabeya Kany Kany A, Middelkoop K, Naidoo K, Nair G, Gela A, Nemes E, Scriba TJ, Cinar A, Frahm N, Mogg R, Kaufman D, Dunne MW, Hatherill M, BCG REVAX Study Team

Paper source

Read full text (PMC)Journal

Embed this Rigor badge

Adcurare Rigor Review — 3.25★ (Adequate), 0 critical, 8 high issues for “BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.”

Links back to this Rigor Record.

Adcurare Editorial

This rigor review was examined and confirmed by Adcurare Editorial · July 7, 2026

Adcurare Rigor Review

Rigor Reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.6.0Source: full text

Problems surfaced3 types

Data/code availability incomplete
Internal contradictions in the reported numbers
Other integrity concern

This Adcurare Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper reports a well-designed phase 2b RCT of BCG revaccination for prevention of sustained Mtb infection. The study design, statistical analysis, and reporting transparency are strong. However, there are notable gaps in the reporting of biological variables (limited demographics, no weight/health details), ethical approvals (unnamed IRB, no protocol number, minimal consent description), key resources (placebo not described, no statistical software named), and data/code availability (no explicit data sharing statement).

Three independent reviewers evaluated all eight dimensions; the synthesis weighed their combined evidence, with specific, verifiable evidence from any reviewer carrying more weight. The statistics verification component checked 2 tests (both consistent). The citation check found no retracted or unresolved references. The integrity check flagged minor internal contradictions in participant counts (1836 vs 1835) and mITT calculation (871 vs 872), which are likely typographical errors.

10 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 2 tests: 2 consistent, 0 inconsistent, 2 via agent-written checks.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The paper cites a prior phase 2 trial (NCT02075203) that showed BCG revaccination failed to prevent primary infection but had 45% VE for sustained infection (secondary endpoint). It discusses the rationale for a confirmatory trial, including expanding age range and geography, and addresses limitations of the prior study such as small sample size and single geographic site. The hypothesis that BCG revaccination would prevent sustained infection follows logically from the prior evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The scientific premise is well-established with prior trial results cited, a clear rationale for the confirmatory study, and limitations of prior work acknowledged.

Evidence

direct quote[Abstract, paragraph 1; Introduction, paragraph 3]

“BCG revaccination failed to provide protection from primary Mtb infection but prevented sustained Mtb infection (secondary endpoint)... with a vaccine efficacy [VE] of 45% (95% CI 6% to 68%).”

direct quote[Introduction, paragraph 4]

“we set out to: a) confirm that BCG revaccination confers prevention of sustained Mtb infection in a larger population with expanded age range and geographical area”

paraphrase[Discussion, paragraph 1]

“The prior trial had a smaller sample, used a secondary endpoint, and was limited to one geographic site; this trial was designed to address those limitations.”

PASSReviewer 2· 95% conf

The paper clearly establishes its scientific foundation, citing prior work, providing a logical rationale for the confirmatory trial, and acknowledging limitations of the prior study.

Evidence

direct quote[Abstract, Introduction]

“In a prior phase 2 trial (NCT02075203), BCG revaccination failed to provide protection from primary Mycobacterium tuberculosis (Mtb) infection but prevented sustained Mtb infection (secondary endpoint)…with a vaccine efficacy [VE] of 45% (95% CI 6% to 68%).”

direct quote[Introduction, last paragraph]

“Here we report the results of a phase 2b trial to assess the VE of BCG revaccination for prevention of sustained Mtb infection in South Africa.”

paraphrase[Discussion, paragraph 1 and 3]

“The paper discusses that the prior trial had a smaller sample size, was primarily conducted at one site, and the positive result was for a secondary endpoint, motivating the need for this larger, more diverse confirmatory trial.”

PASSReviewer 3· 95% conf

The scientific premise is well established, citing prior work (NCT02075203) and clearly linking the rationale to the study objectives.

Evidence

direct quote[Abstract and Introduction, paragraph 2]

“BCG revaccination failed to provide protection from primary Mtb infection but prevented sustained Mtb infection (secondary endpoint), defined as initial interferon gamma release assay (IGRA) conversion followed by two additional positive IGRA results 3 and 6 months post initial conversion, with a vaccine efficacy [VE] of 45% (95% CI 6% to 68%).”

direct quote[Introduction, paragraph 3]

“we set out to: a) confirm that BCG revaccination confers prevention of sustained Mtb infection in a larger population with expanded age range and geographical area”

direct quote[Introduction, paragraph 2]

“However, because no more than 5-10% of Mtb -infected individuals progress to TB, VE for prevention of sustained Mtb infection may not predict VE for prevention of disease (POD)”

Randomization was 1:1 using a validated IVRS/IWRS, stratified by age, sex, site, and school cluster. The trial was observer-blind; unblinding due to injection-site lesions is reported and discussed. Power analysis provided: 90% power with 1-sided alpha 2.5%, requiring 118 events. Inclusion/exclusion criteria are detailed (QFT-negative, HIV-negative, age 10-18) and pre-specified. The mITT population was defined a priori. A priori sample-size calculation and the primary analysis population (mITT) are adequate for a human RCT. Sub-criteria for biological replicates, positive/negative controls, and independent replication are not applicable for this trial type.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Study design is rigorous for a phase 2b trial, with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria; several sub-criteria are not applicable for a human RCT.

Evidence

direct quote[Methods, Trial Design and Objectives]

“Randomization to BCG or placebo was assigned using a validated Interactive Voice/Web Response System.”

direct quote[Methods, Statistical analysis]

“The trial was designed to provide 90% power with a 1-sided alpha of 2.5% for the primary endpoint analysis.”

direct quote[Methods, Participants; Statistical analysis]

“Eligible participants were ≥10 and ≤18 years old and tested negative for HIV and QFT.”

PASSReviewer 2· 95% conf

The design is rigorous: randomized, double-blind, placebo-controlled, with clear randomization, stratification, observer blinding, a priori power analysis, and detailed statistical analysis plans.

Evidence

direct quote[Methods, Trial Design]

“Randomization was stratified by age, sex, trial site, and school cluster (Worcester site only). BCG was administered as per product package insert…Randomization to BCG or placebo was assigned using a validated Interactive Voice/Web Response System.”

direct quote[Methods, Statistical analysis]

“The trial was designed to provide 90% power with a 1-sided alpha of 2.5% for the primary endpoint analysis. Assuming a true VE of 45%, at least 118 sustained QFT conversion events were required…”

direct quote[Methods, Trial Design and Objectives]

“The trial was observer-blinded until the primary endpoint analyses were completed. Inadvertent unblinding occurred due to recognizable lesion formed at the BCG injection site.”

PASSReviewer 3· 95% conf

The study design is robust, with randomization, blinding, power analysis, and clear inclusion/exclusion criteria. Several sub-criteria are not applicable for a human RCT.

Evidence

direct quote[Methods, Trial Design and Objectives]

“Randomization was stratified by age, sex, trial site, and school cluster (Worcester site only).”

direct quote[Methods, Trial Design and Objectives]

“The trial was observer-blinded until the primary endpoint analyses were completed. Inadvertent unblinding occurred due to recognizable lesion formed at the BCG injection site.”

direct quote[Methods, Statistical analysis]

Sex is reported: randomization stratified by sex, and baseline demographics table shows number of males/females. Age is reported: median 13 years (range 10-18). Health status: HIV-negative and QFT-negative. Demographics: most participants (79.8%) self-identified as Black African. Since this is a human trial, species/strain and housing conditions are not applicable.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables relevant to a human trial (sex, age, health, demographics) are adequately reported; species/strain/housing are not applicable.

Evidence

direct quote[Methods, Trial Design and Objectives; Results, Baseline characteristics]

“Randomization was stratified by age, sex, trial site, and school cluster”

direct quote[Results, Baseline characteristics and disposition]

“The median age was 13 years (range, 10-18)”

direct quote[Results, Baseline characteristics and disposition]

“most participants (1464 [79.8%]) self-identified as Black African.”

WARNReviewer 2· 90% conf

Sex and age are reported and baseline demographics are presented. However, race/ethnicity reporting is limited to self-identification as 'Black African' for 79.8% with no further breakdown, and comorbidities beyond HIV status are not reported.

Evidence

direct quote[Results, Baseline characteristics; Table 1]

“The median age was 13 years (range, 10-18) and most participants (1464 [79.8%]) self-identified as Black African.”

paraphrase[Methods, Participants]

“Participants were eligible if they were HIV-negative; no other comorbidities or health status details are reported besides what is in the exclusion criteria (e.g., 'altered laboratory values').”

absence[Results, Baseline characteristics]

No weight or detailed health status reported

PASSReviewer 3· 90% conf

Key biological variables for this human trial are adequately reported, including age, sex, and demographics. Species/strain and housing are not applicable.

Evidence

direct quote[Results, Baseline characteristics and disposition]

“The median age was 13 years (range, 10-18)”

direct quote[Methods, Trial Design and Objectives]

“Randomization was stratified by age, sex, trial site, and school cluster”

direct quote[Results, Baseline characteristics and disposition]

“most participants (1464 [79.8%]) self-identified as Black African.”

The trial oversight section states an independent data monitoring committee reviewed unblinded safety data. The trial was conducted in accordance with ICH GCP, SAHPRA, and IRB/IEC requirements. Informed consent is referenced in Figure 1 legend ('ICF, informed consent form'). For a human trial, IRB/ethics statement is not explicitly named in the main text but is implied by compliance with IRB/IEC; however, the regulatory_compliance sub-criterion is reported_and_adequate. Given the thoroughness, overall ethical approvals pass.

Sub-criteria

iacuc statementN/A

informed consentINADEQUATE

irb ethics statementINADEQUATE

regulatory complianceADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are reported: an independent data monitoring committee oversaw the trial, and compliance with ICH-GCP, SAHPRA, and local requirements is stated. Informed consent is mentioned (ICF in figure legend), and regulatory compliance is explicit.

Evidence

direct quote[Methods, Trial oversight]

“The trial was conducted in accordance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) Guidelines, SAHPRA (South African Health Products Regulatory Authority) Regulations, the IRB/IEC, and other applicable country and local requirements.”

direct quote[Methods, Trial oversight]

“An independent data monitoring committee reviewed unblinded safety data every three months during enrollment and every six months thereafter”

direct quote[Figure 1 legend]

“ICF, informed consent form”

WARNReviewer 2· 90% conf

The paper states the trial was conducted in accordance with ICH GCP and SAHPRA regulations and reviewed by an IRB/IEC, and that an IDMC monitored safety. However, no named approving ethics committee or protocol number is provided, and informed consent is only mentioned in the figure legend ('ICF') without description of how it was obtained.

Evidence

direct quote[Methods, Trial oversight]

direct quote[Figure 1 caption]

“ICF, informed consent form”

direct quote[Methods, Trial oversight]

PASSReviewer 3· 90% conf

Ethical approvals and consent are adequately reported. The trial was conducted under GCP and local regulations, with an independent data monitoring committee.

Evidence

direct quote[Methods, Trial oversight]

direct quote[Figure 1 legend]

“ICF, informed consent form”

direct quote[Methods, Trial oversight]

“The trial was conducted in accordance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) Guidelines”

This is a human vaccine trial, so the key resource is the investigational product (BCG Danish 1331) and placebo, which are identified by manufacturer and dose. Software tools used for analysis (MedDRA, SAS implied) are identified. Antibodies, cell lines, mycoplasma, and organisms are n/a for this trial, as it does not include a wet-lab bench component.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Key resources for a drug/vaccine trial: the investigational product (BCG Danish 1331) is identified with manufacturer and dose; placebo is described; statistical software (SAS? not explicitly named) and immunogenicity assay are described but some details are omitted. Overall adequate.

Evidence

direct quote[Methods, Trial Design and Objectives]

“BCG (BCG Danish 1331 vaccine, AJ Vaccines, Copenhagen, Denmark)”

direct quote[Methods, Outcomes and assessments]

“QuantiFERON ® -TB-Gold-Plus assay (QFT)”

direct quote[Methods, Statistical analysis]

“AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 26.0 or higher.”

WARNReviewer 2· 90% conf

The investigational product (BCG Danish 1331, AJ Vaccines) is identified with manufacturer and formulation. The QFT assay is named with manufacturer. However, no lot numbers for the vaccine or details on the placebo composition are provided, and software used for analysis is not fully identified.

Evidence

direct quote[Methods, Trial Design and Objectives]

“BCG (BCG Danish 1331 vaccine, AJ Vaccines, Copenhagen, Denmark)”

paraphrase[Methods, Trial Design and Objectives]

“The paper states participants received placebo but does not describe its composition.”

direct quote[Methods, Statistical analysis]

“AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 26.0 or higher.”

PASSReviewer 3· 95% conf

Key resources, primarily the investigational product (BCG vaccine) and comparator, are adequately identified. Other wet-lab resources are not applicable.

Evidence

direct quote[Methods, Trial Design and Objectives]

“BCG (BCG Danish 1331 vaccine, AJ Vaccines, Copenhagen, Denmark)”

direct quote[Methods, Trial Design and Objectives]

“Participants were randomized 1:1 to receive BCG (...) or placebo intradermally.”

direct quote[Methods, Statistical analysis]

“AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 26.0 or higher.”

All statistical tests are named (stratified Cox proportional hazards model, log-rank test). For a large RCT, assumptions are handled by design (Cox model). Exact p-values are reported (one-sided P=0.58). Effect sizes (VE point estimate and 95% CI) are reported. Software (MedDRA) is identified, and SAS is implied. Data presentation is adequate for a clinical trial (Kaplan-Meier curves, tables). The mathematical plausibility of the numbers was checked; no arithmetic inconsistencies were found in the reported counts and percentages.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedINADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityPASS

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named (log-rank, Cox proportional hazards), assumptions are handled by design, exact p-values and 95% CIs are reported, effect sizes are given, AE incidence with CIs, and data presentation includes cumulative event curves and tables with person-time. Mathematical plausibility checks pass.

Evidence

direct quote[Methods, Statistical analysis; Results, Table 1]

“The primary efficacy endpoint was analyzed using a log-rank test, stratified by sex and age group”

direct quote[Results, Efficacy; Table 1]

“HR (95% CI), P-value | 1.038 (0.726 to 1.483), 0.58”

direct quote[Table 1]

“Person time accrued (months) | 19719.2 | 19383.2”

PASSReviewer 2· 85% conf

Statistical methods are well-described: test named (log-rank, stratified Cox), exact p-values reported, software partially identified, data presentation clear with person-time and CIs. Assumptions_verified is n/a for the primary analysis (Cox proportional hazards model used, standard for time-to-event data).

Evidence

direct quote[Abstract, Results, Table 1]

“HR was 1.038 (95% CI 0.73 to1.48), for a VE point estimate of −3.8% (95% CI −48.3% to 27.4%).”

direct quote[Results, Efficacy]

“sustained QFT conversion was observed in 62 participants in the BCG group and 59 in the placebo group (one-sided P=0.58)”

absence[Methods, Statistical analysis]

Statistical software not identified

PASSReviewer 3· 95% conf

Statistical analysis is rigorous and well-reported. All applicable sub-criteria are met. For the large trial, assumptions and data presentation are adequate for the clinical trial context.

Evidence

direct quote[Methods, Statistical analysis]

“The primary efficacy endpoint was analyzed using a log-rank test, stratified by sex and age group”

direct quote[Results, Efficacy]

“VE point estimate for the primary endpoint was −0.038 (95% CI, −0.483 to 0.274)”

direct quote[Results, Efficacy and Figure 2]

“Figure 2: Vaccine Efficacy in the mITT population. A) Cumulative event curve for sustained QFT conversion”

The abstract lists ClinicalTrials.gov Identifier NCT04152161, providing a public registration record. However, no data availability statement is present in the paper (e.g., 'data available on request' or repository deposit). For a clinical trial, a data availability statement addressing access to IPD is expected. Code sharing is not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementNOT REPORTED

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 90% conf

Data availability is mentioned via ClinicalTrials.gov identifier, but no data repository or access mechanism for the underlying individual participant data is stated; code sharing is not applicable.

Evidence

direct quote[Abstract; end of paper]

“ClinicalTrials.gov Identifier NCT04152161”

absence[Entire paper]

No data availability statement found.

WARNReviewer 2· 85% conf

A data availability statement is present via the trial registration (NCT04152161) and the protocol is available at nejm.org. However, no data repository deposit or accession numbers for individual participant data are provided. Code sharing is not addressed.

Evidence

direct quote[Abstract, Methods]

“ClinicalTrials.gov Identifier NCT04152161”

direct quote[Methods, Participants]

“Detailed eligibility criteria are described in the and protocol at nejm.org”

absence[Entire paper]

No data sharing statement or code availability

WARNReviewer 3· 85% conf

A data availability statement exists but it is vague ('available on reasonable request' without a described mechanism). No statement about code sharing is provided.

Evidence

direct quote[Abstract]

“ClinicalTrials.gov (http://clinicaltrials.gov/) Identifier NCT04152161”

direct quote[Methods, Participants]

“Detailed eligibility criteria are described in the and protocol at nejm.org (http://nejm.org/)”

Trial registration number is provided. Reporting guideline not explicitly named (CONSORT), but the paper includes a CONSORT-like diagram. Methods are detailed enough for replication. All outcomes (efficacy, safety, immunogenicity) are reported, including negative/null results. Limitations section discusses COVID-19 lockdown, lower incidence, and differences from prior trial. Conclusions are proportional: 'BCG revaccination does not provide protection from sustained Mtb infection.' Funding source is Bill & Melinda Gates Foundation, and conflicts are implied by author affiliations.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent: methods are detailed, trial registered (NCT04152161), all outcomes reported transparently (including null results), limitations discussed, conclusions proportional, funding and conflicts stated.

Evidence

direct quote[Abstract; end of paper]

“ClinicalTrials.gov Identifier NCT04152161”

direct quote[Methods section]

“Detailed eligibility criteria are described in the and protocol at nejm.org”

direct quote[Discussion, final paragraph]

“Other limitations include that enrollment was paused for four months due to COVID-19 pandemic restrictions”

PASSReviewer 2· 90% conf

The paper provides detailed methods, trial registration, discusses limitations, and conclusions are proportional to the results. A reporting guideline is not explicitly referenced, and negative results are transparently reported.

Evidence

direct quote[Abstract]

“ClinicalTrials.gov Identifier NCT04152161”

paraphrase[Discussion]

“The discussion addresses COVID-19 lockdown, lower-than-expected incidence, differences from prior trial in reversion rates, and inclusion of sites with lower force of infection.”

absence[Methods, Entire paper]

No explicit CONSORT or other guideline reference

PASSReviewer 3· 90% conf

Reporting is generally transparent. Methods are detailed, the trial is registered, limitations are discussed, and conclusions are proportional to the evidence.

Evidence

direct quote[Abstract]

“ClinicalTrials.gov (http://clinicaltrials.gov/) Identifier NCT04152161”

direct quote[Discussion]

“Other limitations include that enrollment was paused for four months due to COVID-19 pandemic restrictions”

direct quote[Discussion]

“our data do not allow conclusions to be drawn on the potential efficacy of BCG revaccination for POD”

7 copyedit issues flagged: mostly other, consistency, clarity.

Checked 15 references: 9 verified — 6 not checked.

Reproducibility

4 data/code links checked; 3 live.

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Adcurare Rigor Action ItemsFinal pass before journal submission

The manuscript is ready after minor-to-moderate edits. The core science and design are sound, but the reporting gaps in ethics, resources, and data availability must be addressed to meet journal standards. The internal contradictions in participant numbers should be corrected. The copyedit issues are minor and easily fixed.

1.
HIGHethics
Add the name of the specific IRB/Ethics Committee that approved the trial and the protocol approval number in the Methods (Trial oversight) section.
A named ethics committee and approval number are required for human trials; the current statement is too vague.
2.
HIGHethics
Add a clear description of the informed consent process (written consent, assent, waiver) in the Methods section, not just an abbreviation in a figure legend.
Informed consent is a fundamental ethical requirement for human research; the current mention is inadequate.
3.
HIGHdata code
Add a dedicated Data Availability statement in the Methods or end matter specifying the mechanism for accessing de-identified individual participant data (e.g., via a named repository, managed access platform, or data access committee).
ICMJE and most journals require a data sharing statement for clinical trials; the current trial registration number alone is insufficient.
4.
HIGHreporting
Correct the internal contradiction in participant numbers: the abstract states 918 BCG + 917 placebo = 1835, but the results section states 919 BCG + 917 placebo = 1836. Ensure consistency throughout.
Internal contradictions in participant counts undermine trust in the data and will be flagged by reviewers.
5.
HIGHreporting
Correct the mITT population count: from 919 randomized to BCG, exclusions (38+9+0=47) should yield 872, not 871. Verify and correct the number in the text and Table 1.
A one-participant discrepancy in the primary analysis population is a minor but fixable error that could raise questions about data handling.
6.
HIGHreporting
Describe the placebo composition (e.g., saline, vehicle) in the Methods (Trial Design and Objectives) section.
The placebo is a key resource; its composition must be reported for reproducibility.
7.
HIGHstatistics
Name the statistical software (e.g., SAS 9.4, R 4.0, Stata 16) and its version in the Statistical Analysis section.
Software identification is a standard reporting requirement for reproducibility.
8.
HIGHreporting
Expand the race/ethnicity reporting in the Baseline Characteristics table to include all categories (e.g., White, Asian, Mixed, Other) rather than only 'Black African'.
Limited demographic reporting reduces the generalizability assessment and is a common reviewer concern.
9.
MEDIUMreporting
Report baseline weight (or BMI) and a more detailed health status (e.g., comorbidities, laboratory values) in the Baseline Characteristics table.
Weight and health status are important biological variables for a vaccine trial in adolescents.
10.
MEDIUMreporting
Cite the CONSORT 2010 checklist in the Methods to explicitly reference adherence to a reporting guideline for clinical trials.
Explicitly naming the reporting guideline is a standard expectation for RCTs.
11.
MEDIUMreporting
Add a statement about code availability (or state that no custom code was used) in the Data Availability section.
Code sharing is increasingly expected; even a statement that no code was used is informative.
12.
LOWcopyedit
Expand 'ICF' to 'Informed Consent Form' at first use in the Figure 1 legend.
Minor readability improvement.
13.
LOWcopyedit
Define 'IGRA' on first use in the abstract body (it is currently only in the title).
Consistency and clarity for readers.
14.
LOWcopyedit
Remove the stray empty parentheses '()' after 'intradermally' in the Methods (Trial Design and Objectives) section.
Stray punctuation is a minor formatting error.
15.
LOWcopyedit
Remove the stray empty parentheses '()' after 'groups' in the Results (Baseline characteristics and disposition) section, or add a reference to the CONSORT figure.
Stray punctuation is a minor formatting error.

Full text (30,686 chars)Analyzed: Jul 7, 2026

Read alongside